{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:15:25Z","timestamp":1788318925968,"version":"build-2803163510"},"reference-count":61,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>With the introduction of COVID\u201019 vaccines, there has been a proliferation of quantitative benefit\u2010risk assessments (qBRAs). Prior work on other types of vaccines has found that published qBRAs have not always clearly reported methods and\/or results needed to assist in the application of the qBRA findings. The aim was to systematically identify, review, and critically assess published COVID\u201019 vaccine qBRA. The ultimate goal is to support the future development of robust qBRA for existing, new, and updated vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically reviewed COVID\u201019 vaccine qBRAs identified from multiple sources through April 17, 2023, including literature databases, selected Health Authority websites, and a grey literature search. We critically assessed whether key features typical of qBRA were presented in these reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified 37 COVID\u201019 vaccine qBRAs from screening 2220 publications and 18 other sources. The qBRAs were conducted on two mRNA and two adenoviral vector COVID\u201019 vaccines. Only one qBRA represented low\u2010 and middle\u2010income countries. Although many qBRAs used simple calculations (\n                      <jats:italic>n<\/jats:italic>\n                      = 25), more complex models were presented in 15 reports. Simple approaches were able to employ stratification by age and\/or sex to highlight safety issues affecting specific demographic groups and scenarios to account for changes in viral transmission and vaccine effectiveness over time. Details regarding data sources and analytic methods were missing or limited in some reports.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This comprehensive description and critical assessment of COVID\u201019 vaccine qBRAs together with available guidance can be used to support the development of robust and transparent future vaccine qBRAs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pds.70099","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T19:32:27Z","timestamp":1738179147000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative Benefit\u2013Risk Assessment of Vaccination Against\n                    <scp>COVID<\/scp>\n                    \u201019: A Systematic Review"],"prefix":"10.1002","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8486-6471","authenticated-orcid":false,"given":"E. Claire","family":"Newbern","sequence":"first","affiliation":[{"name":"Johnson &amp; Johnson Innovative Medicine, Global Epidemiology  Horsham Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2097-8674","authenticated-orcid":false,"given":"Lea","family":"Wildisen","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Innovative Medicine  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Verstraeten","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Innovative Medicine  Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Willame","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Innovative Medicine  Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Haynes","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Innovative Medicine, Global Epidemiology  Horsham Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bennett","family":"Levitan","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Innovative Medicine  Titusville New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7271-4186","authenticated-orcid":false,"given":"Nicolas","family":"Praet","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Innovative Medicine  Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010020\u201000984\u20107"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620976951"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.07.041"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.794"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.887"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.05.094"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.09.039"},{"key":"e_1_2_9_9_1","unstructured":"World Health Organization (WHO) \u201cCOVID\u201019 Cases|WHO COVID\u201019 Dashboard. Datadot \u201daccessed November 14 2023 https:\/\/covid19.who.int\/."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643\u2010016\u20100384\u20104"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_9_12_1","unstructured":"Australian Government \u201cWeighing Up the Potential Benefits Against Risk of Harm From COVID\u201019 Vaccine AstraZeneca \u201d(2021) https:\/\/www.rosestreetclinic.com.au\/wp\u2010content\/uploads\/2021\/07\/covid\u201019\u2010vaccination\u2010weighing\u2010up\u2010the\u2010potential\u2010benefits\u2010against\u2010risk\u2010of\u2010harm\u2010from\u2010covid\u201019\u2010vaccine\u2010astrazeneca_2.pdf."},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/jme\u20102022\u2010108449"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010022\u201007823\u20103"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10060845"},{"key":"e_1_2_9_16_1","unstructured":"S.Devriese F.Hulstaert D.Roberfroid J.\u2010M.Dogn\u00e9 J.Hamdani andT. F.Musuamba \u201cRisk Benefit in Context for TTS Events Applied to the Johnson & Johnson Vaccine Summary for the Inter\u2010Ministerial Conference on Public Health \u201d(2021) https:\/\/kce.fgov.be\/sites\/default\/files\/2021\u201011\/TTS_risk_contextualisation_JJ_report.pdf."},{"key":"e_1_2_9_17_1","unstructured":"European Medicine Agency (EMA)\u2014Committee for Medicinal Products for Human Use (CHMP) \u201cAssessment Report EMA\/CHMP\/214855\/2021 \u201d(2021) https:\/\/www.ema.europa.eu\/en\/documents\/opinion\u2010any\u2010scientific\u2010matter\/use\u2010vaxzevria\u2010prevent\u2010covid\u201019\u2010article\u201053\u2010procedure\u2010assessment\u2010report_en.pdf."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.03.030"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/01410768211052589"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03789\u201021"},{"key":"e_1_2_9_21_1","unstructured":"Department of Heath and Social Care \u201cJCVI Statement on COVID\u201019 Vaccination of Children and Young People \u201d(2021) https:\/\/www.gov.uk\/government\/publications\/jcvi\u2010update\u2010on\u2010advice\u2010for\u2010covid\u201019\u2010vaccination\u2010of\u2010children\u2010and\u2010young\u2010people\/jcvi\u2010statement\u2010on\u2010covid\u201019\u2010vaccination\u2010of\u2010children\u2010and\u2010young\u2010people\u201022\u2010december\u20102022."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2022.05.020"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13759"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.10.079"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010022\u201011374\u20107"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100381"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.07.013"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7017e4"},{"key":"e_1_2_9_29_1","unstructured":"M.Mammen \u201cJanssen COVID\u201019 Vaccine Advisory Committee on Immunization Practices \u201d(2021) https:\/\/stacks.cdc.gov\/view\/cdc\/107506."},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.04.004"},{"key":"e_1_2_9_31_1","unstructured":"J.Moon V.Stephens andK.Rogers \u201cA Quantitative Benefit\u2010Risk Analysis & Benefit\u2010Risk Ratio Using Real World Data: Part 2\u2014COVID\u201019 Vaccine Benefit\u2010Risk. Pharmaceutical Online \u201d(2021) https:\/\/www.pharmaceuticalonline.com\/doc\/a\u2010quantitative\u2010benefit\u2010risk\u2010analysis\u2010benefit\u2010risk\u2010ratio\u2010using\u2010real\u2010world\u2010data\u2010part\u2010covid\u2010vaccine\u2010benefit\u2010risk\u20100001."},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2022.03.002"},{"key":"e_1_2_9_33_1","unstructured":"S. E.Oliver \u201cUpdates to the Benefit\/Risk Assessment for Janssen COVID\u201019 Vaccines: Applying the Evidence to Recommendation Framework \u201d(2021) https:\/\/stacks.cdc.gov\/view\/cdc\/112667."},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7103a4"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100393"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9060618"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7032e4"},{"key":"e_1_2_9_38_1","unstructured":"H.Rosenblum \u201cPfizer\u2010BioNTech COVID\u201019 Vaccine and Myocarditis in Individuals Aged 16\u201329\u2009Years: Benefits\u2010Risk Discussion \u201d(2021) https:\/\/stacks.cdc.gov\/view\/cdc\/109495."},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10020140"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541\u2010022\u201000517\u20106"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10122029"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10010081"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560\u20107917.es.2021.26.26.2100533"},{"key":"e_1_2_9_44_1","unstructured":"M.WallaceandS.Oliver \u201cCOVID\u201019 mRNA Vaccines in Adolescents and Young Adults: Benefit\u2010Risk Discussion \u201d(2021) https:\/\/stacks.cdc.gov\/view\/cdc\/108331."},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7111a4"},{"key":"e_1_2_9_46_1","unstructured":"Winton Centre for Risk and Evidence Communication \u201cCommunicating the Potential Benefits and Harms of the Astra\u2010Zeneca COVID\u201019 Vaccine \u201d(2021) https:\/\/wintoncentre.maths.cam.ac.uk\/news\/communicating\u2010potential\u2010benefits\u2010and\u2010harms\u2010astra\u2010zeneca\u2010covid\u201019\u2010vaccine\/."},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7045e1"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1101\/2022.12.02.22283050"},{"key":"e_1_2_9_49_1","unstructured":"Centers for Disease Control and Prevention (CDC) \u201cCOVID Data Tracker \u201daccessed November 14 2023 https:\/\/covid.cdc.gov\/covid\u2010data\u2010tracker\/#datatracker\u2010home."},{"key":"e_1_2_9_50_1","unstructured":"European Centre for Disease Prevention and Control (ECDC) \u201cCOVID\u201019 \u201daccessed November 14 2023 https:\/\/www.ecdc.europa.eu\/en\/covid\u201019."},{"key":"e_1_2_9_51_1","unstructured":"WHO \u2013 Uppsala Monitoring Center (UMC) \u201cVigiBase \u201daccessed November 14 2023."},{"key":"e_1_2_9_52_1","unstructured":"Vaccine Adverse Event Reporting System (VAERS) accessed November 14 2023 https:\/\/vaers.hhs.gov\/."},{"key":"e_1_2_9_53_1","unstructured":"Centers for Disease Control and Prevention (CDC) \u201cMyocarditis and Pericarditis After mRNA COVID\u201019 Vaccination \u201daccessed November 14 2023 https:\/\/www.cdc.gov\/coronavirus\/2019\u2010ncov\/vaccines\/safety\/myocarditis.html."},{"key":"e_1_2_9_54_1","unstructured":"WHO \u201cCOVID\u201019 Subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS): Updated Guidance Regarding Myocarditis and Pericarditis Reported With COVID\u201019 mRNA Vaccines \u201d(2021) https:\/\/www.who.int\/news\/item\/09\u201007\u20102021\u2010gacvs\u2010guidance\u2010myocarditis\u2010pericarditis\u2010covid\u201019\u2010mrna\u2010vaccines."},{"key":"e_1_2_9_55_1","unstructured":"UK Health Security Agency \u201cInformation for Healthcare Professionals on Blood Clotting Following COVID\u201019 Vaccination \u201d(2022) https:\/\/www.gov.uk\/government\/publications\/covid\u201019\u2010vaccination\u2010blood\u2010clotting\u2010information\u2010for\u2010healthcare\u2010professionals\/information\u2010for\u2010healthcare\u2010professionals\u2010on\u2010blood\u2010clotting\u2010following\u2010covid\u201019\u2010vaccination."},{"key":"e_1_2_9_56_1","unstructured":"United Nations \u201cUN Analysis Shows Link Between Lack of Vaccine Equity and Widening Poverty Gap \u201d(2022) https:\/\/news.un.org\/en\/story\/2022\/03\/1114762."},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010023\u201001290\u20108"},{"key":"e_1_2_9_58_1","unstructured":"Food and Drug Administration (FDA) \u201cBenefit\u2010Risk Assessment for New Drug and Biological Products\u2014Guidance for Industry \u201d(2023) https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/benefit\u2010risk\u2010assessment\u2010new\u2010drug\u2010and\u2010biological\u2010products."},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010020\u201000982\u20109"},{"key":"e_1_2_9_60_1","unstructured":"Centers for Disease Control and Prevention (CDC) \u201cData Modernization Initiative \u201daccessed November 14 2023 https:\/\/www.cdc.gov\/surveillance\/data\u2010modernization\/index.html."},{"key":"e_1_2_9_61_1","unstructured":"The European Health Data & Evidence Network (EHDEN) accessed November 14 2023 https:\/\/www.ehden.eu\/#."},{"key":"e_1_2_9_62_1","unstructured":"Observational Health Data Sciences and Informatics (OHDSI) accessed November 14 2023 https:\/\/www.ohdsi.org\/."}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70099","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.70099","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:44:18Z","timestamp":1788317058000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.70099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1002\/pds.70099"],"URL":"https:\/\/doi.org\/10.1002\/pds.70099","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"2024-09-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70099"}}